Conference Coverage
about 18 hours ago
Q&A: Ronald Anglade, MD, on genetic testing in male infertilityabout 21 hours ago
BCG-naïve NMIBC: Optimizing initial treatment selectionLatest News
Nov 11, 2026 | News
Q&A: Ronald Anglade, MD, on genetic testing in male infertility
BCG-naïve NMIBC: Optimizing initial treatment selection
Nov 11, 2026
Survey: Service members and veterans with NMIBC report barriers to treatment access
Nov 11, 2026
Q&A: Suzanne B. Merrill, MD, FACS, on perioperative therapy in MIBC
Nov 10, 2026
FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection
Nov 10, 2026
Advertisement
Shorts
1:14
Why urine cfRNA may be more reliable than urine tumor DNA
17 hours ago
by
Maximilian Diehn, MD, PhD
0:23
BCG-naïve NMIBC: Priorities for improving outcomes
2 days ago
by
Vignesh T. Packiam, MD
0:30
Why BPH treatment after pelvic radiation is challenging
3 days ago
by
Reem Khondakar, MD
0:24
Why Dr. Spier wanted to lead LUGPA
5 days ago
by
Jeffrey M. Spier, MD
0:19
Phone agents and report automation: Starting AI in practice
6 days ago
by
Jared Olafsson, MS
0:20
Genomics over volume in intensifying prostate cancer therapy
6 days ago
by
Benjamin Garmezy, MD
0:44
From liver to kidney: The next questions for histotripsy
7 days ago
by
William C. Huang, MD
0:39
Making the most of networking at the LUGPA Annual Meeting
9 days ago
by
Benjamin H. Lowentritt, MD, FACS
0:20
New guidelines recognize penoscrotal decompression for priapism
10 days ago
by
Juan J. Andino, MD, MBA
0:35
Administrators, coordinators, and lab directors at LUGPA
13 days ago
by
Benjamin H. Lowentritt, MD, FACS
From GSM guidance to HRT reform: A landmark year for women’s health
2025 featured multiple advancements in women's health aimed at enhancing treatment options and awareness.
Inguinal lymph node dissection in penile cancer
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
Inside HoLEP: Irina Jaeger, MD, discusses patient selection and technique
Jaeger emphasizes that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication.
Videos
Urology Times Digital Edition
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
"The overall 0% impact to urology does not help urology practices deal with increasing costs incurred for staff, rent, supplies, and other overhead," write Jonathan Rubenstein, MD, and Mark Painter.
"If 2025 showed us anything, it is the power of combining scientific progress with public engagement," writes Michael S. Cookson, MD, MMHC, FACS.
"Once money is in a Roth IRA, the withdrawal rules depend on whether the funds are contributions, conversions, or earnings," writes Julie Khazan, CFP.
The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial.
The ExactVu micro-ultrasound platform demonstrated noninferior detection of clinically significant prostate cancer vs MRI.
"The OBBA includes broad and sweeping changes that will have a profound impact," writes Allan Shen, CFP.
The ENDURE 1 study plans to enroll up to 60 patients with benign ureteric strictures.
The phase 3 PSMAddition trial assessed the combination of 177Lu-PSMA-617 plus ADT/ARPI in an earlier stage of metastatic prostate cancer.
Jaeger emphasized that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication
Advertisement
All News
Advertisement
Pasritamig is being evaluated with or without JNJ-9401 in the ongoing phase 3 KLK2-comPAS trial.
The combination of nogapendekin alfa inbakicept plus BCG demonstrated a statistically significant improvement in efficacy vs BCG alone.
These FAQs outline key recommendations from ASTRO's updated guideline on shorter-course radiation therapy for localized prostate cancer.
Patient goals, disease features, and response to prior therapy guide treatment choices across high-risk NMIBC, according to Suzanne B. Merrill, MD, FACS.
Suzanne B. Merrill, MD, discusses emerging perioperative approaches in MIBC and the potential for more personalized treatment selection based on disease characteristics.
BCG monotherapy and a high-quality TURBT remain the foundation for BCG-naive high-risk NMIBC, according to Vignesh T. Packiam, MD.
Independent urology practices head into 2027 facing a conversion factor cut, prior authorization hurdles, and Part B drug price negotiation, according to Gary Kirsh, MD.
Updated CAPItello-281 data support capivasertib plus abiraterone in PTEN-deficient mHSPC, according to Daniel J. George, MD.
Benjamin Garmezy, MD, discusses personalizing mHSPC treatment intensification based on disease burden, molecular biomarkers, and patient-specific factors.
Patient priorities and practice logistics should guide therapy selection in BCG-unresponsive NMIBC, according to Katie S. Murray, DO, MS, FACS.
Advertisement
Biomarkers including HRR mutations, PTEN loss, and PSMA expression can guide triplet selection in mHSPC, according to Benjamin Garmezy, MD.
William Huang, MD, discusses histotripsy for renal tumors, the #HOPE4KIDNEY trial, and the technology’s potential to preserve kidney function.
Systemic therapy now anchors MIBC care and expands bladder preservation options, according to Joshua J. Meeks, MD, PhD.
BCG optimization should precede checkpoint inhibitor intensification in BCG-naive high-risk NMIBC, according to Tom Jayram, MD.
Alicia Morgans, MD, discusses ARACOG findings on cognitive outcomes with darolutamide vs enzalutamide and the influence of genetic dementia risk.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection
2
Survey: Service members and veterans with NMIBC report barriers to treatment access
3
BCG-naïve NMIBC: Optimizing initial treatment selection
4
Q&A: Ronald Anglade, MD, on genetic testing in male infertility
5